Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

KY61559X1045
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG00XQZQTS9
MLTX
MoonLake Immunotherapeutics
GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
MoonLake Immunotherapeutics
ISIN
KY61559X1045
TICKER
MLTX
MIC
XNAS
REUTERS
MLTX.OQ
BLOOMBERG
MLTX US
Wed, 24.06.2026       Moonlake Immunotherapeutics
KY61559X1045

ZUG, Switzerland, June 23, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases, today announced the pricing of an underwritten public offering of 9,000,000 Class A ordinary shares at a public offering price per share...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 22.06.2026       Moonlake Immunotherapeutics
KY61559X1045

ZUG, Switzerland, June 22, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases, today announced a proposed public offering of $150 million of its Class A ordinary shares and, in lieu of Class A ordinary shares to cert...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Sun, 21.06.2026       Moonlake Immunotherapeutics
KY61559X1045

ZUG, Switzerland, June 21, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (MoonLake or the Company), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced the Week 52 results of the Phase 3 VELA-1 and VELA-2 clinical trials of its registrational global program in patients with...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Sun, 10.05.2026       Moonlake Immunotherapeutics
KY61559X1045

ZUG, Switzerland, May 10, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake” or the “Company”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced a positive outcome of its final pre-BLA meeting held on April 1, 2026, with the FDA on the HS program of its Nanobody® S...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 28.03.2026       Moonlake Immunotherapeutics
KY61559X1045

ZUG, Switzerland, March 28, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (MoonLake or the Company), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announces long-term Week 40 results of the Phase 3 VELA-1 and VELA-2 clinical trials of its registrational global program in patient...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Sun, 22.02.2026       Moonlake Immunotherapeutics
KY61559X1045

ZUG, Switzerland, February 22, 2026 – MoonLake Immunotherapeutics (NASDAQ:MLTX) (“MoonLake” or the “Company”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announces topline results from the S-OLARIS Phase 2 trial of SLK in patients with radiographic and non-radiographic axSpA and...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 02.02.2026       Moonlake Immunotherapeutics
KY61559X1045

ZUG, Switzerland, February 2, 2026 – MoonLake Immunotherapeutics (NASDAQ:MLTX) (“MoonLake” or the “Company”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announces that the FDA has granted Fast Track designation for sonelokimab for the treatment of moderate‑to‑severe PPP. MoonLake...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 15.12.2025       Moonlake Immunotherapeutics
KY61559X1045

SAN FRANCISCO, Dec. 15, 2025 /PRNewswire/ -- Global plaintiffs' rights firm Hagens Berman reminds investors that the Lead Plaintiff Deadline in the securities class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) is rapidly approaching: December 15, 2025....
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 15.12.2025       Moonlake Immunotherapeutics
KY61559X1045

The DJS Law Group reminds investors of a class action lawsuit against MoonLake Immunotherapeutics (“MoonLake” or “the Company”) (NASDAQ: MLTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of MLTX du...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 15.12.2025       Moonlake Immunotherapeutics
KY61559X1045

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Reuters Research Inc. (“MoonLake” or the “Company”) (NASDAQ: MLTX) and reminds investors of the December 15, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. This...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Mon, 15.12.2025       Moonlake Immunotherapeutics
KY61559X1045

NEW YORK, Dec. 15, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX).  Shareholders who purchased shares of MLTX during the class period listed are encour...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 15.12.2025       Moonlake Immunotherapeutics
KY61559X1045

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against MoonLake Immunotherapeutics (“MoonLake” or “the Company”) (NASDAQ: MLTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commiss...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Sun, 14.12.2025       Moonlake Immunotherapeutics
KY61559X1045

San Francisco, California--(Newsfile Corp. - December 14, 2025) - Global plaintiffs' rights firm Hagens Berman reminds investors that the Lead Plaintiff Deadline in the securities class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) is rapidly approaching: December 15, 2025. The lawsuit alleges that MoonLake and certain executive...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Sun, 14.12.2025       Moonlake Immunotherapeutics
KY61559X1045

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in MoonLake to Contact Him Directly to Discuss Their OptionsIf you purchased or acquired securities in MoonLake between March 10, 2024 and September 29, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partne...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Sun, 14.12.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - December 14, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in MoonLake, you are...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 13.12.2025       Moonlake Immunotherapeutics
KY61559X1045

The Law Offices of Frank R. Cruz reminds investors of the upcoming December 15, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired MoonLake Immunotherapeutics ("MoonLake" or the Company") (NASDAQ: MLTX) securities between March 10, 2024 and September 29, 2025, inc...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 12.12.2025       Moonlake Immunotherapeutics
KY61559X1045

NEW YORK, Dec. 12, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 12.12.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - December 12, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline....
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 12.12.2025       Moonlake Immunotherapeutics
KY61559X1045

SAN FRANCISCO, Dec. 12, 2025 /PRNewswire/ -- Global plaintiffs' rights firm Hagens Berman reminds investors that the Lead Plaintiff Deadline in the securities class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) is rapidly approaching: December 15, 2025....
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 12.12.2025       Moonlake Immunotherapeutics
KY61559X1045

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In MoonLake To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in MoonLake between March 10, 2024 and September 29, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partn...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Fri, 12.12.2025       Moonlake Immunotherapeutics
KY61559X1045

NEW YORK, Dec. 12, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 12.12.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - December 12, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in MoonLake, you are...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 11.12.2025       Moonlake Immunotherapeutics
KY61559X1045

NEW YORK, Dec. 11, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX). Shareholders who purchased shares of MLTX during the class period listed are encoura...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 11.12.2025       Moonlake Immunotherapeutics
KY61559X1045

PHILADELPHIA, Dec. 11, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake" or the "Company") on behalf of investors who purchased MoonLake shares during the period of March 10, 2024 through September 29, 2025 (the "Class Period")....
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 11.12.2025       Moonlake Immunotherapeutics
KY61559X1045

LOS ANGELES, Dec. 11, 2025 /PRNewswire/ -- The DJS Law Group  reminds investors of a class action lawsuit against  MoonLake Immunotherapeutics ("MoonLake " or "the Company") (NASDAQ: MLTX ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 11.12.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - December 10, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline....
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 10.12.2025       Moonlake Immunotherapeutics
KY61559X1045

Global plaintiffs' rights firm Hagens Berman reminds investors that the Lead Plaintiff Deadline in the securities class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) is rapidly approaching: December 15, 2025. The lawsuit alleges that MoonLake and certain executives made materially false and misleading statements regarding the...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 10.12.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - December 10, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in MoonLake, you are...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 10.12.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - December 9, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline.SO WHA...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 10.12.2025       Moonlake Immunotherapeutics
KY61559X1045

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In MoonLake To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in MoonLake between March 10, 2024 and September 29, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partne...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 09.12.2025       Moonlake Immunotherapeutics
KY61559X1045

Lead Partner Reed Kathrein Investigating Alleged Undisclosed Truth: Did SLK's Nanobody Structure Truly Confer a Superior Clinical Benefit Over Monoclonal Antibodies?SAN FRANCISCO, Dec. 9, 2025 /PRNewswire/ -- Global plaintiffs' rights law firm Hagens Berman reminds investors that the deadline to move the Court for appointment as lead plaintiff in...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 09.12.2025       Moonlake Immunotherapeutics
KY61559X1045

NEW YORK, Dec. 9, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 08.12.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - December 8, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline.S...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 08.12.2025       Moonlake Immunotherapeutics
KY61559X1045

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in MoonLake to Contact Him Directly to Discuss Their OptionsIf you purchased or acquired securities in MoonLake between March 10, 2024 and September 29, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partne...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 08.12.2025       Moonlake Immunotherapeutics
KY61559X1045

LOS ANGELES, Dec. 8, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) have opportunity to lead the securities fraud class action lawsuit. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN MOONLAKE (MLTX) CLICK HERE BEFORE DECEM...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 08.12.2025       Moonlake Immunotherapeutics
KY61559X1045

NEW YORK, Dec. 8, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX). Shareholders who purchased shares of MLTX during the class period listed are encourag...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 08.12.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - December 8, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in MoonLake, you are e...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 08.12.2025       Moonlake Immunotherapeutics
KY61559X1045

LOS ANGELES, Dec. 8, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against MoonLake Immunotherapeutics ("MoonLake" or "the Company") (NASDAQ: MLTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder b...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Sun, 07.12.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - December 7, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline.S...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Sun, 07.12.2025       Moonlake Immunotherapeutics
KY61559X1045

NEW YORK, Dec. 7, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 06.12.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - December 6, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline.S...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 06.12.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - December 6, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in MoonLake, you are e...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 05.12.2025       Moonlake Immunotherapeutics
KY61559X1045

NEW YORK, Dec. 5, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 05.12.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - December 5, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline.S...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 05.12.2025       Moonlake Immunotherapeutics
KY61559X1045

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In MoonLake To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in MoonLake between March 10, 2024 and September 29, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partn...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 05.12.2025       Moonlake Immunotherapeutics
KY61559X1045

MLTX Investor with Losses Encourages to Contact Firm by Dec. 15 DeadlineSAN FRANCISCO, Dec. 5, 2025 /PRNewswire/ -- Global plaintiffs' rights law firm Hagens Berman reminds investors that the deadline to move the Court for appointment as lead plaintiff in the securities class action lawsuit against MoonLake Immunotherapeutics, Inc. (NASDAQ: MLTX)...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 04.12.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - December 4, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in MoonLake, you are e...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 04.12.2025       Moonlake Immunotherapeutics
KY61559X1045

NEW YORK, Dec. 4, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX). Shareholders who purchased shares of MLTX during the class period listed are encourag...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 04.12.2025       Moonlake Immunotherapeutics
KY61559X1045

LOS ANGELES, Dec. 4, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against MoonLake Immunotherapeutics ("MoonLake " or "the Company") (NASDAQ: MLTX ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. S...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 04.12.2025       Moonlake Immunotherapeutics
KY61559X1045

LOS ANGELES, Dec. 4, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against MoonLake Immunotherapeutics ("MoonLake" or "the Company") (NASDAQ: MLTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder b...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink